Previously, we isolated a panel of monoclonal antibodies, termed ADPs, with high binding activity to human ADAM8, no cross-reactivity to closely related ADAM family members and strong inhibitory activity, for development into an ADAM8-targeted cancer therapy (manuscript in preparation). This evidence concerns the gene ADAM8 and cancer.